“…The carboplatin/etoposide regimen was used when the Temozolamide was not available. The survival pattern of our population joins the other populations in several points such as the slight better outcome for women compared to men 6,25 , the decrease survival with increasing age 6,11 , and increasing grade of malignancy 14,19 and survival of GBM 17,[26][27][28] . Nonetheless, the minor fluctuations observed when comparing the cohort to others become more accentuated when it comes to the OS (mean = 45.4 months, median = 21.7, survival rates at 1-, 2-, and 5-years of 62.8%, 48.5% and 32.9% respectively) found to be higher than the European (1-and 5-years survival = 56.9% and 19.6%, respectively) and the Tunisian (mean = 27 months, 1-, 2-and 5-years survival rates : 42%, 30% and 26% respectively) 6,11,14,17,19,26 .…”